• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Inspections, Compliance, Enforcement, and Criminal Investigations

  • Print
  • Share
  • E-mail

Lincoln County Medical Center 15-Feb-02


Public Health Service

Food and Drug Administration


Office of the Regional

Food and Drug Director

7920 Elmbrook Drive, Suite 102

Dallas, TX 75247-4982

TELEPHONE. 214655-8100

FACSIMILE: 214-655-8130

February 15, 2002




RE: Inspection ID ? 1743340008

David G. Blackman

Radiology Manager

Lincoln County Medical Center

211 Sudderth

Ruidoso, NM 88345

Dear Mr. Blackman,

On January 23, 2002, a representative of the Food and Drug Administration (FDA) inspected your facility. This inspection revealed a serious regulatory problem involving the mammography at your facility.

The Mammography Quality Standards Act of 1992 requires your facility to meet specific

standards. These requirements help protect the health of women by assuring that a facility can perform quality mammography. The inspection revealed the following repeated level 2 finding at your facility:

Level 2 repeat: 2 of 5 random reports reviewed did not contain an acceptable assessment


The specific problem noted above appeared on your MQSA Facility Inspection Report, which was issued to your facility at the close of the inspection,

[A finding is considered a repeat finding if the same type of violation was cited during the previous inspection, whether or not the finding is associated with the same piece of equipment (x-ray unit, processor, or darkroom) or the same personnel in a given category.]

Level 2 repeat findings may be symptomatic of serious underlying problems that could

compromise the quality of mammography at your facility. They represent a serious violation of the law which may result in FDA taking regulatory action without further notice to you. These actions include, but are not Iimited to:

- Placing your facility under a Directed Plan of Correction.

- Charging your facility for the cost of on-site monitoring.

- Assessing civil money penalties up to $10,000 for each failure to substantially comply with, or each day of failure to substantially comply with, the Standards-

- Suspension or revocation of your facility? s FDA certificate, or obtaining a court injunction against further mammography.

In addition, your response should address the level 2 -finding that was listed on the inspection report provided to you at the close of the inspection. The inspection revealed the following level 2 finding:

Level 2: Failed to produce documents verifying that the radiologic technologist [redacted] (5 CEU? s in 36 months) met the continuing education requirement of having taught or completed at least 15 continuing education units in mammography in 36 months.

It is necessary for you to act on this matter immediately. You are required to respond to this office in writing within fifteen (15) working days from receipt of this letter. Please address the following:

- The specific steps you have taken to correct all of the violations noted in this letter.

- Each step your facility is taking to prevent the recurrence of similar violations.

- Equipment settings (including technique factors), raw test data, and calculated final results, where appropriate.

- Sample records that demonstrate proper record keeping procedures, if the findings relate to quality control or other records (Note: Patient names-or identification should be deleted from any copies submitted).

Please submit your response to:

Deborah M. McGee, Radiation Specialist

Food and Drug Administration

7920 Elmbrook Drive, Suite 102

Dallas, TX 75247-4982

This letter pertains only to findings of your inspection and does not necessarily address other obligations you have under the law. You may obtain general information about all of FDA?s requirements for mammography facilities by contacting the Mammography Quality Assurance Program, Food and Drug Administration, P.O. Box 6057, Columbia, MD 21045-6057 (l-800-838-7715) or through the Internet at http://www.fda.gov.